Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

Stephan R. Vavricka, Martin Gubler, Claudine Gantenbein, Muriel Spoerri, Florian Froehlich, Frank Seibold, Marijana Protic, Pierre Michetti, Alex Straumann, Nicolas Fournier, Pascal Juillerat, Luc Biedermann, Jonas Zeitz, Benjamin Misselwitz, Michael Scharl, Henriette Heinrich, Christine N. Manser, Ekaterina Safroneeva, Raja Affendi Raja Ali, Gerhard Rogler & 2 others Alain M. Schoepfer, Thomas Greuter

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. Methods: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. Results: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). Infliximab was the most frequently used drug (63.2%). In more than 71.8%, a clinical response of the underlying EIM to anti-TNF therapy was observed. In 92 patients (43.2%), anti-TNF treatments were started for the purpose of treating EIM rather than IBD. Response rates to anti-TNF were generally good and best for psoriasis, aphthous stomatitis, uveitis, and peripheral arthritis. In 11 patients, 14 EIM occurred under anti-TNF treatment. Conclusions: Anti-TNF was frequently used among patients with EIM. In more than 40%, anti-TNF treatments are started to treat EIM rather than IBD. Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not seem to be a source of considerable concern.

Original languageEnglish
Pages (from-to)1174-1181
Number of pages8
JournalInflammatory Bowel Diseases
Volume23
Issue number7
DOIs
Publication statusPublished - 1 Jul 2017

Fingerprint

Inflammatory Bowel Diseases
Cohort Studies
Tumor Necrosis Factor-alpha
Therapeutics
Aphthous Stomatitis
Uveitis
Psoriasis
Arthritis
Physicians

Keywords

  • anti-TNF
  • arthritis
  • extraintestinal manifestations
  • inflammatory bowel disease
  • uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Vavricka, S. R., Gubler, M., Gantenbein, C., Spoerri, M., Froehlich, F., Seibold, F., ... Greuter, T. (2017). Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflammatory Bowel Diseases, 23(7), 1174-1181. https://doi.org/10.1097/MIB.0000000000001109

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. / Vavricka, Stephan R.; Gubler, Martin; Gantenbein, Claudine; Spoerri, Muriel; Froehlich, Florian; Seibold, Frank; Protic, Marijana; Michetti, Pierre; Straumann, Alex; Fournier, Nicolas; Juillerat, Pascal; Biedermann, Luc; Zeitz, Jonas; Misselwitz, Benjamin; Scharl, Michael; Heinrich, Henriette; Manser, Christine N.; Safroneeva, Ekaterina; Raja Ali, Raja Affendi; Rogler, Gerhard; Schoepfer, Alain M.; Greuter, Thomas.

In: Inflammatory Bowel Diseases, Vol. 23, No. 7, 01.07.2017, p. 1174-1181.

Research output: Contribution to journalArticle

Vavricka, SR, Gubler, M, Gantenbein, C, Spoerri, M, Froehlich, F, Seibold, F, Protic, M, Michetti, P, Straumann, A, Fournier, N, Juillerat, P, Biedermann, L, Zeitz, J, Misselwitz, B, Scharl, M, Heinrich, H, Manser, CN, Safroneeva, E, Raja Ali, RA, Rogler, G, Schoepfer, AM & Greuter, T 2017, 'Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study', Inflammatory Bowel Diseases, vol. 23, no. 7, pp. 1174-1181. https://doi.org/10.1097/MIB.0000000000001109
Vavricka, Stephan R. ; Gubler, Martin ; Gantenbein, Claudine ; Spoerri, Muriel ; Froehlich, Florian ; Seibold, Frank ; Protic, Marijana ; Michetti, Pierre ; Straumann, Alex ; Fournier, Nicolas ; Juillerat, Pascal ; Biedermann, Luc ; Zeitz, Jonas ; Misselwitz, Benjamin ; Scharl, Michael ; Heinrich, Henriette ; Manser, Christine N. ; Safroneeva, Ekaterina ; Raja Ali, Raja Affendi ; Rogler, Gerhard ; Schoepfer, Alain M. ; Greuter, Thomas. / Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. In: Inflammatory Bowel Diseases. 2017 ; Vol. 23, No. 7. pp. 1174-1181.
@article{060039d3f4a84da99c61664850dac398,
title = "Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study",
abstract = "Background: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. Methods: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. Results: Of the 366 patients with at least 1 EIM, 213 (58.2{\%}) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2{\%} versus 21.0{\%}, P < 0.001). Infliximab was the most frequently used drug (63.2{\%}). In more than 71.8{\%}, a clinical response of the underlying EIM to anti-TNF therapy was observed. In 92 patients (43.2{\%}), anti-TNF treatments were started for the purpose of treating EIM rather than IBD. Response rates to anti-TNF were generally good and best for psoriasis, aphthous stomatitis, uveitis, and peripheral arthritis. In 11 patients, 14 EIM occurred under anti-TNF treatment. Conclusions: Anti-TNF was frequently used among patients with EIM. In more than 40{\%}, anti-TNF treatments are started to treat EIM rather than IBD. Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not seem to be a source of considerable concern.",
keywords = "anti-TNF, arthritis, extraintestinal manifestations, inflammatory bowel disease, uveitis",
author = "Vavricka, {Stephan R.} and Martin Gubler and Claudine Gantenbein and Muriel Spoerri and Florian Froehlich and Frank Seibold and Marijana Protic and Pierre Michetti and Alex Straumann and Nicolas Fournier and Pascal Juillerat and Luc Biedermann and Jonas Zeitz and Benjamin Misselwitz and Michael Scharl and Henriette Heinrich and Manser, {Christine N.} and Ekaterina Safroneeva and {Raja Ali}, {Raja Affendi} and Gerhard Rogler and Schoepfer, {Alain M.} and Thomas Greuter",
year = "2017",
month = "7",
day = "1",
doi = "10.1097/MIB.0000000000001109",
language = "English",
volume = "23",
pages = "1174--1181",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

AU - Vavricka, Stephan R.

AU - Gubler, Martin

AU - Gantenbein, Claudine

AU - Spoerri, Muriel

AU - Froehlich, Florian

AU - Seibold, Frank

AU - Protic, Marijana

AU - Michetti, Pierre

AU - Straumann, Alex

AU - Fournier, Nicolas

AU - Juillerat, Pascal

AU - Biedermann, Luc

AU - Zeitz, Jonas

AU - Misselwitz, Benjamin

AU - Scharl, Michael

AU - Heinrich, Henriette

AU - Manser, Christine N.

AU - Safroneeva, Ekaterina

AU - Raja Ali, Raja Affendi

AU - Rogler, Gerhard

AU - Schoepfer, Alain M.

AU - Greuter, Thomas

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. Methods: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. Results: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). Infliximab was the most frequently used drug (63.2%). In more than 71.8%, a clinical response of the underlying EIM to anti-TNF therapy was observed. In 92 patients (43.2%), anti-TNF treatments were started for the purpose of treating EIM rather than IBD. Response rates to anti-TNF were generally good and best for psoriasis, aphthous stomatitis, uveitis, and peripheral arthritis. In 11 patients, 14 EIM occurred under anti-TNF treatment. Conclusions: Anti-TNF was frequently used among patients with EIM. In more than 40%, anti-TNF treatments are started to treat EIM rather than IBD. Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not seem to be a source of considerable concern.

AB - Background: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. Methods: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. Results: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). Infliximab was the most frequently used drug (63.2%). In more than 71.8%, a clinical response of the underlying EIM to anti-TNF therapy was observed. In 92 patients (43.2%), anti-TNF treatments were started for the purpose of treating EIM rather than IBD. Response rates to anti-TNF were generally good and best for psoriasis, aphthous stomatitis, uveitis, and peripheral arthritis. In 11 patients, 14 EIM occurred under anti-TNF treatment. Conclusions: Anti-TNF was frequently used among patients with EIM. In more than 40%, anti-TNF treatments are started to treat EIM rather than IBD. Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not seem to be a source of considerable concern.

KW - anti-TNF

KW - arthritis

KW - extraintestinal manifestations

KW - inflammatory bowel disease

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=85021287769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021287769&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000001109

DO - 10.1097/MIB.0000000000001109

M3 - Article

VL - 23

SP - 1174

EP - 1181

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 7

ER -